Oxea

Oxeia Biopharma is a clinical-stage biotechnology company focused on developing first-in-class therapies for mild traumatic brain injury (mTBI), commonly known as concussion. The company's lead program, OXE-103, is a synthetic human ghrelin that targets the metabolic and neuroendocrine dysfunction associated with brain injuries. By addressing the underlying pathophysiology of concussions, Oxeia aims to reduce the duration and severity of symptoms, particularly for patients at high risk of prolonged recovery. The company is currently advancing OXE-103 through Phase 2 clinical trials to establish its efficacy in treating acute concussion and post-concussion syndrome.